Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches
- 27 April 2012
- journal article
- review article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 53 (4) , 537-549
Abstract
Chronic lymphocytic leukemia (CLL) remains associated with low complete response rates and high relapse rates. This is in part due to poor understanding of CLL biology and thus inadequate targeting of therapy. For years CLL has been proposed as bi-compartmental: the quiescent tumor in the periphery and the proliferating cells within specific microenvironments. Historically the bone marrow was considered the major tissue of the CLL microenvironment. However, many recent innovative studies have categorically shown that peripheral CLL cells are derived from the lymph nodes (LN). Proliferation here is largely driven by helper T cells via CD40–CD40L engagement. Critically, in vitro studies have shown that such engagement additionally protects LN CLLs from apoptosis. Agents inducing apoptosis in non-CD40 engaged CLL cells are frequently ineffective against those continually engaged with CD40L. This emphasizes that, in order to improve responses and prevent relapse, novel therapies must be assessed against CD40L engaged CLL cells to show effective targeting against the LN. This review discusses the evidence supporting the superior involvement of the LN in CLL, how CD40L engaged CLL studies should be conducted, and the novel therapies studied in vitro and in vivo that have been proposed to be effective in this setting.Keywords
This publication has 139 references indexed in Scilit:
- Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaClinical Cancer Research, 2011
- Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemiaCell Death & Differentiation, 2010
- HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen speciesNature Immunology, 2010
- Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological FeaturesClinical Cancer Research, 2010
- Molecular footprints of a germinal center derivation of human IgM+(IgD+)CD27+ B cells and the dynamics of memory B cell generationJournal of Experimental Medicine, 2009
- Common community acquired infections and subsequent risk of chronic lymphocytic leukaemiaBritish Journal of Haematology, 2009
- The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cellsBlood, 2008
- Sympathetic modulation of immunity: Relevance to diseaseCellular Immunology, 2008
- Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implicationsBlood, 2006
- Human splenic marginal zone B cells lack expression of activation‐induced cytidine deaminaseEuropean Journal of Immunology, 2005